Mal-PEG8-Phe-Lys-PAB-Exatecan (TFA)
Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) [1].
Product Specifications
UNSPSC
12352005
Target
Drug-Linker Conjugates for ADC; Topoisomerase
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mal-peg8-phe-lys-pab-exatecan-tfa.html
Purity
98.66
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C=CC1=O)N1CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCCN)C(NC(C=C3)=CC=C3COC(N[C@@H]4C5=C6C(C(N7C6)=CC([C@](O)(C(OC8)=O)CC)=C8C7=O)=NC9=CC(F)=C(C)C(CC4)=C95)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
Molecular Formula
C75H93F4N9O22
Molecular Weight
1548.58
References & Citations
[1]Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1. |[2]Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Camptothecins
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
